OCA
BIOA

Octagon Capital Advisors’s BioAge Labs BIOA Stock Holding History

Octagon Capital Advisors’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.6M Buy
1,748,000
+150,000
+9% +$2.89M 3.38% 10
2025
Q4 		$21.1M Buy
+1,598,000
New +$14.2M 2.57% 15

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Octagon Capital Advisors's BIOA Position: Q1 2026 in Review

Octagon Capital Advisors increased its BioAge Labs (BIOA) stake by 9.4% in Q1 2026, buying an estimated $2.89M and bringing the position to 1,748,000 shares worth $30.6M. The position accounts for 3.38% of the portfolio, ranked #10.

Octagon Capital Advisors first reported a position in BIOA in Q4 2025 and has held it in 2 quarters since. 144 funds tracked by Wall St. Rank hold BIOA as of Q1 2026.

  • Octagon Capital Advisors held 1,748,000 shares of BioAge Labs worth $30.6M as of Q1 2026.
  • Octagon Capital Advisors bought 150,000 BioAge Labs shares in Q1 2026, an estimated $2.89M.
  • BioAge Labs made up 3.38% of Octagon Capital Advisors's portfolio in Q1 2026, its #10 holding.
  • Octagon Capital Advisors first reported a position in BioAge Labs in Q4 2025 and has held it in 2 quarters since.
  • 144 funds tracked by Wall St. Rank held BioAge Labs as of Q1 2026.

Based on Octagon Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.